Next project IDH1_2-pyridinone to#2 characterization of TOX of potential anticancer compounds following multiple dose admin to rats, 1/18/17-6/30/18, pre-clin TOX study of drug DEV for cancer patients…
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Battelle Memorial Institute UEI ZFX8JGFQ89F4 Part of Battelle Memorial Institute
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $248,269
Award facts
- Opportunity
-
- N02CM4700142 Solicitation number
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Apr 4, 2014
- Contract value 100% obligated
- $248,269.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Columbus, OH 43201, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$7,727 | |
| Original award | $255,996 |
About this award
The National Cancer Institute issued a delivery order to Battelle Memorial Institute on January 25, 2017, with a ceiling value of $248,269.21, under the Toxicology of Drugs Developed for Cancer Patients indefinite delivery contract for characterization of toxicology of potential anticancer compounds.
The order is a pre-clinical toxicology study of drug development for cancer patients, involving multiple-dose administration to rats. Place of performance is Columbus, Ohio. The period of performance runs from January 18, 2017, through June 30, 2018. The order is priced on a cost-plus-fixed-fee basis with no set-aside.
Description
Next project IDH1_2-pyridinone to#2 characterization of TOX of potential anticancer compounds following multiple dose admin to rats, 1/18/17-6/30/18, pre-clin TOX study of drug DEV for cancer patients HHSN261201600016I DTP-17-007 TPB
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Battelle Memorial Institute by National Cancer Institute (National Institutes of Health) on January 25, 2017.
How much is contract HHSN26100002 worth?
The government has obligated $248,269 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201600016I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award